Jenburkt Pharmaceuticals balance sheet

As of Mar 2026

Total assets: ₹226cr+15.2% on Mar 2025
Total debt: ₹0.0cr−100.0% on Mar 2025
Cash and investments: ₹5.6cr−24.3% on Mar 2025
Cash from operations: ₹26.5cr−5.0% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	46.1	40.3	1.2	1.0
	0.2	0.2	0.4	0.2
	27.0	20.6	16.8	11.2
	0.0	0.0	0.0	0.1
	34.7	59.9	0.7	25.6
	1.3	2.8	25.5	12.0
	13.6	8.9	8.6	8.3
	24.4	20.7	19.5	17.0
	5.6	7.4	4.1	3.7
	47.5	17.3	75.1	50.2
	0.1	0.1	0.1	0.1
	0.4	0.4	0.8	0.8
	3.4	1.7	1.4	0.9
	226	196	165	142
Equity
	4.4	4.4	4.4	4.4
	193	167	141	118
Liabilities
	3.0	3.0	3.0	2.9
	1.0	1.1	0.8	0.7
	0.0	2.0	0.0	2.4
	8.1	8.2	6.3	6.1
	5.4	4.7	5.3	4.9
	6.6	1.6	0.9	0.3
	1.1	0.3	1.6	0.3
	1.3	1.7	2.2	1.2
	226	196	165	142

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JENBURPH₹875.95

Jenburkt Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA KPL MAKERSL NOVARTIND PARNAXLAB SGRL SHUKRAPHAR SUNLOC

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Non-current Assets
+ Capital Work-in-Progress	1.0	1.2	40.3	46.1
+ Other Intangibles	0.2	0.4	0.2	0.2
+ Non-current Investments	11.2	16.8	20.6	27.0
+ Long-term Loans	0.1	0.0	0.0	0.0
+ Other Non-current Financial Assets	25.6	0.7	59.9	34.7
+ Other Non-current Assets	12.0	25.5	2.8	1.3
Current Assets
+ Inventories	8.3	8.6	8.9	13.6
+ Trade Receivables	17.0	19.5	20.7	24.4
+ Cash & Cash Equivalents	3.7	4.1	7.4	5.6
+ Other Bank Balances	50.2	75.1	17.3	47.5
+ Short-term Loans	0.1	0.1	0.1	0.1
+ Other Current Financial Assets	0.8	0.8	0.4	0.4
+ Other Current Assets	0.9	1.4	1.7	3.4
Total Assets	141.8	165.1	196.2	226.0
Equity
+ Equity Share Capital	4.4	4.4	4.4	4.4
+ Other Equity / Reserves	118.0	140.5	167.4	192.6
Liabilities
+ Other Non-current Financial Liab	2.9	3.0	3.0	3.0
+ Deferred Tax Liabilities	0.7	0.8	1.1	1.0
+ Borrowings — Current	2.4	0.0	2.0	0.0
+ Trade Payables	6.1	6.3	8.2	8.1
+ Other Current Financial Liab	4.9	5.3	4.7	5.4
+ Provisions — Current	0.3	0.9	1.6	6.6
+ Current Tax Liabilities	0.3	1.6	0.3	1.1
+ Other Current Liabilities	1.2	2.2	1.7	1.3
Total Equity & Liabilities	141.8	165.1	196.2	226.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.